‏إظهار الرسائل ذات التسميات Cannabis. إظهار كافة الرسائل
‏إظهار الرسائل ذات التسميات Cannabis. إظهار كافة الرسائل

Cannabis Wellness Startup Awshad Launches Its Cannabis Medicinal Capsules Named 'Calmasule'

Delhi-based cannabis wellness startup Awshad has announced the launch of their new prescription product - a cannabis medicinal capsule line branded as ‘Calmasule’. The objective behind this roll-out of the new product line of Awshad is to help people experience the healing qualities of cannabis in the form of a capsule in order to enable them to alleviate pain, insomnia, stress and various other lifestyle ailments through an all-natural solution and thus aid their overall well-being. Interestingly, the naming of Calmasule is inspired by the first and foremost effect of this capsule, which is to calm down one’s nerves to further help an individual with managing anxiety, pain and sleep issues.

Cannabis Wellness Startup Awshad Launches Its Cannabis Medicinal Capsules Named 'Calmasule',

With this new line of products, Awshad intends to expand its target audience and customer base and thereby increase sales and revenue in order to consolidate market leadership. Thisin turn will help Awshad infuse more resources in educating and spreading awareness to destigmatize cannabis and spread awareness on its myriad wellness benefits, which till date remains the biggest hurdle in this industry.

Awshad has been working with leading cannabis manufacturing and formulation teams in India in a bid to come out with these superlative, pure cannabis extract capsules that have been proven to have very high efficacy and showed extremely promising results amongst the focus groups. Only if and when they have a prescription, the customers would be able to buy Awshad’s newly-launched capsule products directly from the Awshad website or via aggregator marketplaces like CBD Store, It’s Hemp and others.

Awshad’s new range of capsules have been made available under two variants: Calmasule and Calmasule Plus; the main difference between these two variants lies in the concentration/ratio of CBD and THC (both of them being compounds present in cannabis) present in the product. Calmasule is the milder product variant which is more versatile and can be used by a wide range of users. With 10mg CBD and 5mg THC (2:1 CBD: THC ratio), Calmasule helps patients combat anxiety, stress, insomnia and mild pain issues. On the other hand, Calmsule+ is a much stronger product variant with 15mg CBD and 15mg THC (1:1 CBD: THC ratio), thus especially recommended for those facing chronic and more serious ailments like chronic pains, chronic insomnia, Cancer, Parkinson’s, Epilepsy, Arthritis, etc.

Speaking on the launch of the new product, Shivam Singhee, Co-Founder & CEO, Awshad said, “We at Awshad are extremely pleased and excited to introduce our and India’s first cannabis extract-based capsules to the market, called Calmasule and Calmasule Plus. These newly-launched Awshad capsules are meant to derive the best efficacy and results for our discerning Indian customers. Also, these capsules will be the strongest products among our current offerings, and is geared towards people who are looking for highly effective products to deal with their more serious ailments. In the long run, we understand the importance of a variety of products under a trusted brand can lead to bigger market acceptance, and knowing that our customers come from diverse backgrounds and situations, we shall continue to strive to serve them all with appropriate products that will help them achieve their health and wellness goals.”

Richa Jaggi, Co-Founder & CMO, Awshad adds, “As a brand in a nascent industry, it is imperative that we continue to innovate and our biggest inspiration comes from our customers and we always listen to what they require from us. Some of our customers wanted an easier to carry and an easier product to administer (instead of using the dropper for Vijaya Oils). And we also found out that a lot of people are more comfortable with capsules and pills over edible tinctures. We further recognized that we were interacting with a lot of people who are looking for stronger cannabis products in the market, as the current offering isn’t satisfying their needs. Following these findings and active listening to our customers’ feedback, we are glad to now introduce Awshad’s new medicinal cannabis capsules. Looking at the growing acceptance in the market, we are very certain Calmasule will create a huge demand in the Indian cannabis space and help Awshad to consolidate its leadership in the Indian medical cannabis space.”

Notably, Awshad’s dynamic website has multiple onboarded in-house doctors who can help patients to get valid prescriptions for the product, and would also diagnose and provide answers to any queries a patient may have. If one already has a valid prescription, he/she can simply upload the prescription during the checkout process while purchasing the product on the Awshad website.

Previously, Awshad had also launched its flagship prescription product named ‘Awshad Full Spectrum Vijaya Oil’. While Awshad’s Vijaya Oil product offers more value for money and last longer for the consumers, but their latest offering, i.e. the Calmasule capsules are meant for people who prefer pills over edible oils. The Awshad capsules have no taste, are easy to swallow, and would help people with more consistent dosages. In the near future, Awshad will continue to innovate constantly with newer formats of medical cannabis while attempting to move closer to their vision of revolutionizing the wellness sector in India. Notably, all of Awshad’s products are intensively lab-tested and certified by the Ministry of AYUSH, Government of India.

About Awshad

Awshad is a South-Delhi based cannabis wellness startup co-founded and bootstrapped by Shivam Singhee, CEO and Richa Jaggi, CMO. Awshad’s clinically-tested, vegan and gluten-free Full-Spectrum CBD products are made using the highest quality cannabis extract in a bid to provide better health and wellness to people across all ages and backgrounds. However, the products are especially targeted towards those dealing with lifestyle ailments such as stress, insomnia, anxiety, chronic pain, epilepsy and inflammation, among various other lifestyle issues. The startup works with the objective and vision to revolutionize the wellness space in India, while providing profound and long-term physical and mental health and wellness benefits to their customers.

HempStreet Expands Product Portfolio, Launches Sarpagandha Vati, to Combat Hypertension

HempStreet Expands Product Portfolio, Launches Sarpagandha Vati, to Combat Hypertension

HempStreet, India's first research to retail venture in the ayurvedic cannabis sector, has launched Sarpagandha Vati. Coming in the form of a tablet, Sarpagandha Vati helps treat Hypertension and Insomnia due to its calmative properties.

Sarpgandha
HempStreet’s dispensation works through a network of doctors who can buy the product via HempStreet’s B2B channels. This medicine is safe and reliable for middle and even old age people (39-70 years) who are at higher risk of side effects. The classical ayurvedic formulation outperforms other drugs in the same therapeutic range when combined with more potent herbs such as Vijaya (Cannabis Sativa) and Jatamansi (Nardostachys Jatamansi).

Each tablet of ‘Sarpagandha Vati’ contains Sarpagandha (262.20 mg), Khurasani Ajwain (52.44 mg), Jatamansi (26.22 mg), Vijaya (26.22 mg) and Pipalimula (4.92 mg). This Ayurvedic medicine calms the nervous system, aids in the maintenance of normal blood pressure, and maintains oxygen balance that helps regulate blood pressure in hypertensive patients. Additionally, Sarpagandha Vati’s diuretic and detoxifying properties benefit people with the following health and lifestyle issues:
  • Help manage Epilepsy and Delirium
  • Help combat anxiety disorder
  • Help curb the desire for Alcohol
  • Induce natural sleep to defy Insomnia
While conventional medications have serious health consequences, Ayurveda offers a natural, holistic, safe, and effective alternative to alleviate the condition of Hypertension. Sarpagandha Vati aims at providing a reliable and safe ayurvedic solution to hypertensive patients by regulating their blood pressure.

About HempStreet

HempStreet is India's first research to retail medicinal cannabis venture, working towards amalgamating the age-old science of Ayurveda with modern cannabis research to develop sustainable and economical solutions for mass ailments. All of this while ensuring end-to-end blockchain technology-based supply chain tracking to minimize any chance of abuse. HempStreet's dispensation network of more than 11000 partner clinics across 26 states of India is a testament to the efficacy of the formulations and the trust of medical practitioners in the brand. 

The company is also India's first medicinal cannabis venture to have been awarded the prestigious Biotechnology Ignition Grant (BIG) of BIRAC. Recently HempStreet partnered with Gynica, an R&D company based out of Israel focused on changing the culture of gynecological treatment through clinically proven, cannabinoid-based solutions.

Medical Cannabis Startup Hempstreet and Amrita School of Ayurveda Tie-Up to Fight Against Mass Ailments

Through this partnership, HempStreet aims to build solutions to help them in their fight against mass ailments.

HempStreet, India's first research to retail venture in the ayurvedic cannabis sector, has partnered with Amrita School of Ayurveda. Amrita School of Ayurveda, based in Kerala, was founded in 2004 and is a well-known Ayurvedic education facility both nationally and internationally. Through this collaboration, HempStreet aims to receive clinically supported solutions to aid in their fight against mass ailments.

Hempstreet and Amrita School of Ayurveda Tie-Up to Fight Against Mass Ailments

HempStreet started with the vision to harness the power of ayurveda and utilize responsibly dispensed cannabis based medication to tackle chronic ailments. HempStreet’s partnership with Amrita School of Ayurveda is one step further to meet the nation's needs of managing ailments through modern Ayurveda. Amrita School of Ayurveda, part of Amrita University, is ranked fifth in the National Institutional Ranking Framework (NIRF) Rankings 2021. Amrita School takes a unique approach to blending ancient philosophies and health science by cultivating a new breed of Ayurvedic physicians to fulfill the mission of creating a patient-centered and integrated health care delivery system.

Commenting on the partnership, Abhishek Mohan, Founder & CEO, HempStreet, said, “We are very excited to announce this partnership with Amrita School of Ayurveda and its affiliate R&D organizations to work towards clinical validation of formulations to address several mass ailments. This aligns with our policy of partnering with the best in class. With this partnership, we strive to further our mission to harness the power of Ayurveda via cannabis-based medication with a layer of clinical validation. This fits our global strategy of best-in-class partnerships across Europe, the US and Israel.”

Adding to this, Dr P. Ram Manohar, Head, Centre for Advanced Research In Ayurveda (ACARA), said, "We are thrilled to be collaborating with HempStreet. Our goal is to promote the expansion and advancement of Ayurvedic education, and working with HempStreet will help us close the knowledge gap between cutting-edge technological advancements and traditional medicine based on ancient wisdom. By bringing tradition and scientific research together, we can pave the way for contemporizing Ayurveda to meet global health care needs.”

HempStreet is poised to reshape the way mass ailments are addressed by raising awareness about the use of cannabis for pain management to address one of the health sector's most pressing issues. The company recently collaborated with over 400 Ayurvedic doctors in Mumbai to bolster this. Furthermore, to strengthen the R&D and distribution segment, HempStreet also partnered with MGC Pharma and Gynica earlier this year.

About HempStreet

HempStreet is India's first research to retail medicinal cannabis venture, working towards amalgamating the age-old science of Ayurveda with modern cannabis research to develop sustainable and economical solutions for mass ailments. All of this while ensuring end-to-end blockchain technology-based supply chain tracking to minimize any chance of abuse. HempStreet's dispensation network of more than 11000 partner clinics across 26 states of India is a testament to the efficacy of the formulations and the trust of medical practitioners in the brand. The company is also India's first medicinal cannabis venture to have been awarded the prestigious Biotechnology Ignition Grant (BIG) of BIRAC. Recently HempStreet partnered with Gynica, an R&D company based out of Israel focused on changing the culture of gynecological treatment through clinically proven, cannabinoid-based solutions.

About Amrita School of Ayurveda:

Amrita School of Ayurveda, Amritapuri was established in 2004 and managed by Mata Amritanandamayi Math Trust. The college has developed into a prestigious centre for education in Ayurveda, nationally as well as internationally, under the gracious guidance of its founder and spiritual guru, Mata Amritanandamayi Devi. The mission of the school is to provide a value-based education and mold the character of our younger generation through synergy of science and spirituality so that their earnest endeavor to achieve progress and prosperity in life is matched by an ardent desire to extend selfless service to the society, one complementing the other.

Mumbai Angels, Hindustan Media Ventures Pvt Ltd, and others invest in pre-SeriesA round of Hemp Horizons

Mumbai Angels, Hindustan Media Ventures Pvt Ltd, and others invest in pre-SeriesA round of Hemp Horizons

The company will leverage its latest funding to build offline distribution, strengthen its marketing strategies, boost its D2C brand 'Health Horizons' and launch new products

Mumbai Angels, a premium platform for private investments, invests in Hemp Horizons, a vertically integrated, zero waste and carbon-negative pioneer in the domestic hemp industry. The undisclosed funding round that saw the participation from Hindustan Media Ventures Pvt Ltd, and others, will enable Hemp Horizons to build a robust offline distribution network, strengthen marketing strategies, promote its D2C brand 'Health Horizons,' and launch new products.

“With the recent regulatory amendment advancing the recognition of Hemp seed as a nutritional superfood product, the Hemp industry is upbeat about its growth prospects. I am confident that as an established vertically integrated player focused on driving a carbon-negative footprint, Hemp Horizons is set to capitalize on the Hemp revolution for the unabated future growth,” said Nandini Mansinghka, Co-Founder & CEO of Mumbai Angels.

"With this renewed support from our previous investors, Mumbai Angels and Hindustan Media Ventures Pvt Ltd, we are all set to build a much larger organization at Hemp Horizons. We are excited to see how the hemp and cannabis industry has evolved since our inception five years ago. At Hemp Horizons, we don't just sell products but encourage a zero-waste ecosystem. We have created a sustainable foundation with an unbreakable supply chain, in-house GMP, and USFDA-registered manufacturing and packaging facility. Every product we sell comes right from the farm into the customers' hands, and Hemp Horizons is the only channel in between."

"With these fresh funds, we will be building our offline distribution network, which will allow us to create a true D2C system that is sustainable and has a relatively lower carbon footprint. For consumers, I would like to say, read the labels and do your research before buying the products. It's important to know the lifecycle of every product. The Indian hemp and cannabis industry is growing significantly, and soon we will be an exporter to the world,"added Co-Founder & CEO of Hemp Horizons, Rohit Shah.

Founded in 2017, Hemp Horizons is the brainchild of Rohit Shah, Kartikey Dadoo and Kanishk Yadav. It was initially set out to be a vertically integrated company. Over the last five years, the company has witnessed significant growth. It currently operates a 20MT manufacturing facility for hemp seed and cannabis to develop health and wellness products. Hemp Horizons has already collaborated with more than 40 labeling companies to supply their products. Its brand 'Health Horizons' has also recently launched several avant-garde products in India and gained 7000+ D2C clients.

About Mumbai Angels

Started in 2006, Mumbai Angels, India's premier platform for private investment, holds an AUM of USD 130 Mn and a 200+ strong portfolio spanning a wide range of sectors, such as Technology, Consumer, Life Sciences, DefenseTech, SpaceTech, EV, AgriTech, FinTech, EdTech, Gaming and Content, etc. Of the overall portfolio, the platform has exited/secured the next round of funding for 100+ of them. The platform has 700 investors spread across 60+ Global and Indian cities.

CannaDAO Launches World’s 1st Decentralized, Member-Governed Platform for Cannabis Industry

Even as the vast majority of the world is excluded from the benefits of the legal cannabis industry despite significant legal breakthroughs in the past decades CannaDAO today announced the launch of its platform for cannabis growing and operations in a bid to disrupt, destigmatize and decentralize a trillion-dollar industry.

"The community can now disrupt, destigmatize and decentralize a trillion-dollar industry," said Eric Benz, CannaDAO Contributor and former CEO of Changelly, and serial entrepreneur. "The days of targeting stoner culture are no longer and the time to redefine what cannabis means and represents is now. The future of finance is green"
.
The DAO launch is slated for April 20 and will be powered by the Aurora cross-chain bridge running on the NEAR protocol. The DAO will allow the community to participate and earn rewards from real-world operations within the cannabis industry.

Contributors to the project are projecting a $100M Total Value Locked (TVL) in the next 6 to 18 months. In addition to Eric Benz, they include Jon Matonis, Founding Director at the Bitcoin Foundation, and Nicholas Gregory, CEO of CommerceBlock.

Following long struggles for cannabis rights, both in recreational and medical use,
Significant breakthroughs resulted in increased tolerance and legalization across the world, however, even in countries where the cannabis industry is legal, stringent rules, high costs make it difficult to participate in growing operations.

“The hard-fought legal battles around cannabis rights have resulted in significant breakthroughs and increased tolerance around the world,” Benz said. “But the vast majority of the world is still excluded from the benefits of the legal cannabis industry, whether consumers, growers, or businesses. CannaDAO removes the hurdles for so many who want to participate in this blooming economy while at the same time having a strong social impact.”

With a series of NFT releases as well as a P2E game, CannaFarm will launch on March 7 on Aurora. Users will be able to participate in a truly decentralized and gamified governance model. The DAO will drop on April 20 with the governance token ($CANNA) available on Ref.finance.

The governance token $CANNA plays a key role as a utility token allowing members of the CannaDAO to participate in project governance, including the proposal of new cannabis growing opportunities, voting on submitted proposals and funding approvals, and participating in grow operations harvesting yield through token staking. $CANNA will include governance utility interacting within the CannaDAO ecosystem with proposal submissions, voting mechanisms, membership with prestige levels, payment modules for cannabis-related services on and off-chain, transaction visibility, and accountability.

Hempstreet Becomes India's 1st Medical Cannabis Company To Receive Govt Biotech Ignition Grant of Rs.50 Lakh



HempStreet, a research to retail company in the ayurvedic cannabis sector, has received a grant of about Rs 50 lakh from the Government of India for research on cannabis. With this, the company will do research and development work about the use of cannabis in Ayurvedic medicines.

It is the first medical cannabis company that has received the Biotechnology Ignition Grant (BIG) from the Biotechnology Industry Research Assistance Council (BIRAC) of the Government of India for research on cannabis.

With this, the company will do research and development work about the use of cannabis in Ayurvedic medicines. With this, the company will do research and development work about the use of cannabis in Ayurvedic medicines.

Prior to this, Bharat Biotech have received grants from BIG, which were engaged in research and development work of Covid vaccine.

Abhishek Mohan, Co-Founder and CEO, HempStreet said, “This award and the grant validates our efforts to build a world-class organization and take the Indian medical cannabis industry to its rightful place. We want to be a Make in India brand for the world."

Hempstreet claims that it is conducting research with leading scientists of the country about the use of cannabis in the treatment of diseases that affect about 300 million Indians. HempStreet claims to have a network of over 220 Ayurvedic clinics serving around 60,000 doctors across the country and have served about 35 million patients.

Market Reports

Market Report & Surveys
IndianWeb2.com © all rights reserved